http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 05 Mar 2026 03:03:00 +0000 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Nxera+Pharma+to+Receive+US%243+Million+Milestone+Payment+from+Centessa+Pharmaceuticals/26113980.html <p align="justify"><b>Tokyo, Japan and Cambridge, UK, 5 March 2026</b> – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that Centessa Pharmaceuticals has achieved an additional early development milestone associated with its investigational, orally administered, highly potent and selective orexin receptor 2 (OX2R) agonist, ORX489, being developed by Centessa for the treatment of neuropsychiatric disorders. This milestone triggers a payment of US$3 million to Nxera pursuant to its research collaboration with Centessa. The milestone payment will be recognized as revenue in the first quarter of 2026.</p> <p align="center">–END–</p> <p align="justify"><b>About Nxera Pharma</b><br/>Nxera Pharma is a http://www.streetinsider.com/Press+Releases/Nxera+Pharma+to+Receive+US%243+Million+Milestone+Payment+from+Centessa+Pharmaceuticals/26113980.html Thu, 05 Mar 2026 03:03:00 +0000 0ACX 4565 O.05105894 O.49013836 http://www.streetinsider.com/Press+Releases/Nxera+Pharma+to+Receive+US%243+Million+Milestone+Payment+from+Centessa+Pharmaceuticals/26113980.html <p align="justify"><b>Tokyo, Japan and Cambridge, UK, 5 March 2026</b> – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that Centessa Pharmaceuticals has achieved an additional early development milestone associated with its investigational, orally administered, highly potent and selective orexin receptor 2 (OX2R) agonist, ORX489, being developed by Centessa for the treatment of neuropsychiatric disorders. This milestone triggers a payment of US$3 million to Nxera pursuant to its research collaboration with Centessa. The milestone payment will be recognized as revenue in the first quarter of 2026.</p> <p align="center">–END–</p> <p align="justify"><b>About Nxera Pharma</b><br/>Nxera Pharma is a http://www.streetinsider.com/Press+Releases/Nxera+Pharma+to+Receive+US%243+Million+Milestone+Payment+from+Centessa+Pharmaceuticals/26113980.html Thu, 05 Mar 2026 03:03:00 +0000 0ACX 4565 O.05105894 O.49013836 http://www.streetinsider.com/Press+Releases/Nxera+Pharma+to+Receive+US%243+Million+Milestone+Payment+from+Centessa+Pharmaceuticals/26113980.html <p align="justify"><b>Tokyo, Japan and Cambridge, UK, 5 March 2026</b> – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that Centessa Pharmaceuticals has achieved an additional early development milestone associated with its investigational, orally administered, highly potent and selective orexin receptor 2 (OX2R) agonist, ORX489, being developed by Centessa for the treatment of neuropsychiatric disorders. This milestone triggers a payment of US$3 million to Nxera pursuant to its research collaboration with Centessa. The milestone payment will be recognized as revenue in the first quarter of 2026.</p> <p align="center">–END–</p> <p align="justify"><b>About Nxera Pharma</b><br/>Nxera Pharma is a http://www.streetinsider.com/Press+Releases/Nxera+Pharma+to+Receive+US%243+Million+Milestone+Payment+from+Centessa+Pharmaceuticals/26113980.html Thu, 05 Mar 2026 03:03:00 +0000 0ACX 4565 O.05105894 O.49013836 http://www.streetinsider.com/Press+Releases/Nxera+Pharma+to+Receive+US%243+Million+Milestone+Payment+from+Centessa+Pharmaceuticals/26113980.html <p align="justify"><b>Tokyo, Japan and Cambridge, UK, 5 March 2026</b> – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that Centessa Pharmaceuticals has achieved an additional early development milestone associated with its investigational, orally administered, highly potent and selective orexin receptor 2 (OX2R) agonist, ORX489, being developed by Centessa for the treatment of neuropsychiatric disorders. This milestone triggers a payment of US$3 million to Nxera pursuant to its research collaboration with Centessa. The milestone payment will be recognized as revenue in the first quarter of 2026.</p> <p align="center">–END–</p> <p align="justify"><b>About Nxera Pharma</b><br/>Nxera Pharma is a http://www.streetinsider.com/Press+Releases/Nxera+Pharma+to+Receive+US%243+Million+Milestone+Payment+from+Centessa+Pharmaceuticals/26113980.html Thu, 05 Mar 2026 03:03:00 +0000 0ACX 4565 O.05105894 O.49013836 http://www.streetinsider.com/Globe+Newswire/Nxera+Pharma+to+Receive+US%243+Million+Milestone+Payment+from+Centessa+Pharmaceuticals/26113980.html <p align="justify"><b>Tokyo, Japan and Cambridge, UK, 5 March 2026</b> – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that Centessa Pharmaceuticals has achieved an additional early development milestone associated with its investigational, orally administered, highly potent and selective orexin receptor 2 (OX2R) agonist, ORX489, being developed by Centessa for the treatment of neuropsychiatric disorders. This milestone triggers a payment of US$3 million to Nxera pursuant to its research collaboration with Centessa. The milestone payment will be recognized as revenue in the first quarter of 2026.</p> <p align="center">–END–</p> <p align="justify"><b>About Nxera Pharma</b><br/>Nxera Pharma is a http://www.streetinsider.com/Globe+Newswire/Nxera+Pharma+to+Receive+US%243+Million+Milestone+Payment+from+Centessa+Pharmaceuticals/26113980.html Thu, 05 Mar 2026 03:03:00 +0000 0ACX 4565 O.05105894 O.49013836 http://www.streetinsider.com/Globe+Newswire/Nxera+Pharma+to+Receive+US%243+Million+Milestone+Payment+from+Centessa+Pharmaceuticals/26113980.html <p align="justify"><b>Tokyo, Japan and Cambridge, UK, 5 March 2026</b> – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that Centessa Pharmaceuticals has achieved an additional early development milestone associated with its investigational, orally administered, highly potent and selective orexin receptor 2 (OX2R) agonist, ORX489, being developed by Centessa for the treatment of neuropsychiatric disorders. This milestone triggers a payment of US$3 million to Nxera pursuant to its research collaboration with Centessa. The milestone payment will be recognized as revenue in the first quarter of 2026.</p> <p align="center">–END–</p> <p align="justify"><b>About Nxera Pharma</b><br/>Nxera Pharma is a http://www.streetinsider.com/Globe+Newswire/Nxera+Pharma+to+Receive+US%243+Million+Milestone+Payment+from+Centessa+Pharmaceuticals/26113980.html Thu, 05 Mar 2026 03:03:00 +0000 0ACX 4565 O.05105894 O.49013836 http://www.streetinsider.com/Globe+Newswire/Nxera+Pharma+to+Receive+US%243+Million+Milestone+Payment+from+Centessa+Pharmaceuticals/26113980.html <p align="justify"><b>Tokyo, Japan and Cambridge, UK, 5 March 2026</b> – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that Centessa Pharmaceuticals has achieved an additional early development milestone associated with its investigational, orally administered, highly potent and selective orexin receptor 2 (OX2R) agonist, ORX489, being developed by Centessa for the treatment of neuropsychiatric disorders. This milestone triggers a payment of US$3 million to Nxera pursuant to its research collaboration with Centessa. The milestone payment will be recognized as revenue in the first quarter of 2026.</p> <p align="center">–END–</p> <p align="justify"><b>About Nxera Pharma</b><br/>Nxera Pharma is a http://www.streetinsider.com/Globe+Newswire/Nxera+Pharma+to+Receive+US%243+Million+Milestone+Payment+from+Centessa+Pharmaceuticals/26113980.html Thu, 05 Mar 2026 03:03:00 +0000 0ACX 4565 O.05105894 O.49013836 http://www.streetinsider.com/Globe+Newswire/Nxera+Pharma+to+Receive+US%243+Million+Milestone+Payment+from+Centessa+Pharmaceuticals/26113980.html <p align="justify"><b>Tokyo, Japan and Cambridge, UK, 5 March 2026</b> – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that Centessa Pharmaceuticals has achieved an additional early development milestone associated with its investigational, orally administered, highly potent and selective orexin receptor 2 (OX2R) agonist, ORX489, being developed by Centessa for the treatment of neuropsychiatric disorders. This milestone triggers a payment of US$3 million to Nxera pursuant to its research collaboration with Centessa. The milestone payment will be recognized as revenue in the first quarter of 2026.</p> <p align="center">–END–</p> <p align="justify"><b>About Nxera Pharma</b><br/>Nxera Pharma is a http://www.streetinsider.com/Globe+Newswire/Nxera+Pharma+to+Receive+US%243+Million+Milestone+Payment+from+Centessa+Pharmaceuticals/26113980.html Thu, 05 Mar 2026 03:03:00 +0000 0ACX 4565 O.05105894 O.49013836 http://www.streetinsider.com/Press+Releases/Nxera+Pharma+Submits+Marketing+Authorization+Application+for+Daridorexant+in+South+Korea/26106077.html <ul type="disc"><li style="margin-top:22pt;">Daridorexant is a dual orexin receptor antagonist being developed in South Korea by Nxera for the treatment of adult patients with insomnia and is approved and marketed in Japan as QUVIVIQ®</li><li style="margin-top:22pt;">Phase 3 trial of daridorexant in South Korea met both primary and secondary efficacy endpoints of subjective total sleep time (sTST), subjective latency to sleep onset (sLSO) and subjective wake after sleep onset (sWASO)</li></ul> <p align="justify"><b>Tokyo, Japan and Cambridge, UK, 4 March 2026</b> – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that it has submitted a marketing authorisation application (MAA) to the http://www.streetinsider.com/Press+Releases/Nxera+Pharma+Submits+Marketing+Authorization+Application+for+Daridorexant+in+South+Korea/26106077.html Wed, 04 Mar 2026 03:54:00 +0000 4565 A.05768276 A.30594482 O.05105894 O.05733076 O.31501636 http://www.streetinsider.com/Press+Releases/Nxera+Pharma+Submits+Marketing+Authorization+Application+for+Daridorexant+in+South+Korea/26106077.html <ul type="disc"><li style="margin-top:22pt;">Daridorexant is a dual orexin receptor antagonist being developed in South Korea by Nxera for the treatment of adult patients with insomnia and is approved and marketed in Japan as QUVIVIQ®</li><li style="margin-top:22pt;">Phase 3 trial of daridorexant in South Korea met both primary and secondary efficacy endpoints of subjective total sleep time (sTST), subjective latency to sleep onset (sLSO) and subjective wake after sleep onset (sWASO)</li></ul> <p align="justify"><b>Tokyo, Japan and Cambridge, UK, 4 March 2026</b> – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that it has submitted a marketing authorisation application (MAA) to the http://www.streetinsider.com/Press+Releases/Nxera+Pharma+Submits+Marketing+Authorization+Application+for+Daridorexant+in+South+Korea/26106077.html Wed, 04 Mar 2026 03:54:00 +0000 4565 A.05768276 A.30594482 O.05105894 O.05733076 O.31501636 http://www.streetinsider.com/Press+Releases/Nxera+Pharma+Submits+Marketing+Authorization+Application+for+Daridorexant+in+South+Korea/26106077.html <ul type="disc"><li style="margin-top:22pt;">Daridorexant is a dual orexin receptor antagonist being developed in South Korea by Nxera for the treatment of adult patients with insomnia and is approved and marketed in Japan as QUVIVIQ®</li><li style="margin-top:22pt;">Phase 3 trial of daridorexant in South Korea met both primary and secondary efficacy endpoints of subjective total sleep time (sTST), subjective latency to sleep onset (sLSO) and subjective wake after sleep onset (sWASO)</li></ul> <p align="justify"><b>Tokyo, Japan and Cambridge, UK, 4 March 2026</b> – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that it has submitted a marketing authorisation application (MAA) to the http://www.streetinsider.com/Press+Releases/Nxera+Pharma+Submits+Marketing+Authorization+Application+for+Daridorexant+in+South+Korea/26106077.html Wed, 04 Mar 2026 03:54:00 +0000 4565 A.05768276 A.30594482 O.05105894 O.05733076 O.31501636 http://www.streetinsider.com/Press+Releases/Nxera+Pharma+Submits+Marketing+Authorization+Application+for+Daridorexant+in+South+Korea/26106077.html <ul type="disc"><li style="margin-top:22pt;">Daridorexant is a dual orexin receptor antagonist being developed in South Korea by Nxera for the treatment of adult patients with insomnia and is approved and marketed in Japan as QUVIVIQ®</li><li style="margin-top:22pt;">Phase 3 trial of daridorexant in South Korea met both primary and secondary efficacy endpoints of subjective total sleep time (sTST), subjective latency to sleep onset (sLSO) and subjective wake after sleep onset (sWASO)</li></ul> <p align="justify"><b>Tokyo, Japan and Cambridge, UK, 4 March 2026</b> – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that it has submitted a marketing authorisation application (MAA) to the http://www.streetinsider.com/Press+Releases/Nxera+Pharma+Submits+Marketing+Authorization+Application+for+Daridorexant+in+South+Korea/26106077.html Wed, 04 Mar 2026 03:54:00 +0000 4565 A.05768276 A.30594482 O.05105894 O.05733076 O.31501636 http://www.streetinsider.com/Press+Releases/Nxera+Pharma+Submits+Marketing+Authorization+Application+for+Daridorexant+in+South+Korea/26106077.html <ul type="disc"><li style="margin-top:22pt;">Daridorexant is a dual orexin receptor antagonist being developed in South Korea by Nxera for the treatment of adult patients with insomnia and is approved and marketed in Japan as QUVIVIQ®</li><li style="margin-top:22pt;">Phase 3 trial of daridorexant in South Korea met both primary and secondary efficacy endpoints of subjective total sleep time (sTST), subjective latency to sleep onset (sLSO) and subjective wake after sleep onset (sWASO)</li></ul> <p align="justify"><b>Tokyo, Japan and Cambridge, UK, 4 March 2026</b> – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that it has submitted a marketing authorisation application (MAA) to the http://www.streetinsider.com/Press+Releases/Nxera+Pharma+Submits+Marketing+Authorization+Application+for+Daridorexant+in+South+Korea/26106077.html Wed, 04 Mar 2026 03:54:00 +0000 4565 A.05768276 A.30594482 O.05105894 O.05733076 O.31501636 http://www.streetinsider.com/Press+Releases/Nxera+Pharma+Submits+Marketing+Authorization+Application+for+Daridorexant+in+South+Korea/26106077.html <ul type="disc"><li style="margin-top:22pt;">Daridorexant is a dual orexin receptor antagonist being developed in South Korea by Nxera for the treatment of adult patients with insomnia and is approved and marketed in Japan as QUVIVIQ®</li><li style="margin-top:22pt;">Phase 3 trial of daridorexant in South Korea met both primary and secondary efficacy endpoints of subjective total sleep time (sTST), subjective latency to sleep onset (sLSO) and subjective wake after sleep onset (sWASO)</li></ul> <p align="justify"><b>Tokyo, Japan and Cambridge, UK, 4 March 2026</b> – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that it has submitted a marketing authorisation application (MAA) to the http://www.streetinsider.com/Press+Releases/Nxera+Pharma+Submits+Marketing+Authorization+Application+for+Daridorexant+in+South+Korea/26106077.html Wed, 04 Mar 2026 03:54:00 +0000 4565 A.05768276 A.30594482 O.05105894 O.05733076 O.31501636 http://www.streetinsider.com/Globe+Newswire/Nxera+Pharma+Submits+Marketing+Authorization+Application+for+Daridorexant+in+South+Korea/26106077.html <ul type="disc"><li style="margin-top:22pt;">Daridorexant is a dual orexin receptor antagonist being developed in South Korea by Nxera for the treatment of adult patients with insomnia and is approved and marketed in Japan as QUVIVIQ®</li><li style="margin-top:22pt;">Phase 3 trial of daridorexant in South Korea met both primary and secondary efficacy endpoints of subjective total sleep time (sTST), subjective latency to sleep onset (sLSO) and subjective wake after sleep onset (sWASO)</li></ul> <p align="justify"><b>Tokyo, Japan and Cambridge, UK, 4 March 2026</b> – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that it has submitted a marketing authorisation application (MAA) to the http://www.streetinsider.com/Globe+Newswire/Nxera+Pharma+Submits+Marketing+Authorization+Application+for+Daridorexant+in+South+Korea/26106077.html Wed, 04 Mar 2026 03:54:00 +0000 4565 A.05768276 A.30594482 O.05105894 O.05733076 O.31501636 http://www.streetinsider.com/Globe+Newswire/Nxera+Pharma+Submits+Marketing+Authorization+Application+for+Daridorexant+in+South+Korea/26106077.html <ul type="disc"><li style="margin-top:22pt;">Daridorexant is a dual orexin receptor antagonist being developed in South Korea by Nxera for the treatment of adult patients with insomnia and is approved and marketed in Japan as QUVIVIQ®</li><li style="margin-top:22pt;">Phase 3 trial of daridorexant in South Korea met both primary and secondary efficacy endpoints of subjective total sleep time (sTST), subjective latency to sleep onset (sLSO) and subjective wake after sleep onset (sWASO)</li></ul> <p align="justify"><b>Tokyo, Japan and Cambridge, UK, 4 March 2026</b> – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that it has submitted a marketing authorisation application (MAA) to the http://www.streetinsider.com/Globe+Newswire/Nxera+Pharma+Submits+Marketing+Authorization+Application+for+Daridorexant+in+South+Korea/26106077.html Wed, 04 Mar 2026 03:54:00 +0000 4565 A.05768276 A.30594482 O.05105894 O.05733076 O.31501636 http://www.streetinsider.com/Globe+Newswire/Nxera+Pharma+Submits+Marketing+Authorization+Application+for+Daridorexant+in+South+Korea/26106077.html <ul type="disc"><li style="margin-top:22pt;">Daridorexant is a dual orexin receptor antagonist being developed in South Korea by Nxera for the treatment of adult patients with insomnia and is approved and marketed in Japan as QUVIVIQ®</li><li style="margin-top:22pt;">Phase 3 trial of daridorexant in South Korea met both primary and secondary efficacy endpoints of subjective total sleep time (sTST), subjective latency to sleep onset (sLSO) and subjective wake after sleep onset (sWASO)</li></ul> <p align="justify"><b>Tokyo, Japan and Cambridge, UK, 4 March 2026</b> – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that it has submitted a marketing authorisation application (MAA) to the http://www.streetinsider.com/Globe+Newswire/Nxera+Pharma+Submits+Marketing+Authorization+Application+for+Daridorexant+in+South+Korea/26106077.html Wed, 04 Mar 2026 03:54:00 +0000 4565 A.05768276 A.30594482 O.05105894 O.05733076 O.31501636 http://www.streetinsider.com/Globe+Newswire/Nxera+Pharma+Submits+Marketing+Authorization+Application+for+Daridorexant+in+South+Korea/26106077.html <ul type="disc"><li style="margin-top:22pt;">Daridorexant is a dual orexin receptor antagonist being developed in South Korea by Nxera for the treatment of adult patients with insomnia and is approved and marketed in Japan as QUVIVIQ®</li><li style="margin-top:22pt;">Phase 3 trial of daridorexant in South Korea met both primary and secondary efficacy endpoints of subjective total sleep time (sTST), subjective latency to sleep onset (sLSO) and subjective wake after sleep onset (sWASO)</li></ul> <p align="justify"><b>Tokyo, Japan and Cambridge, UK, 4 March 2026</b> – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that it has submitted a marketing authorisation application (MAA) to the http://www.streetinsider.com/Globe+Newswire/Nxera+Pharma+Submits+Marketing+Authorization+Application+for+Daridorexant+in+South+Korea/26106077.html Wed, 04 Mar 2026 03:54:00 +0000 4565 A.05768276 A.30594482 O.05105894 O.05733076 O.31501636 http://www.streetinsider.com/Globe+Newswire/Nxera+Pharma+Submits+Marketing+Authorization+Application+for+Daridorexant+in+South+Korea/26106077.html <ul type="disc"><li style="margin-top:22pt;">Daridorexant is a dual orexin receptor antagonist being developed in South Korea by Nxera for the treatment of adult patients with insomnia and is approved and marketed in Japan as QUVIVIQ®</li><li style="margin-top:22pt;">Phase 3 trial of daridorexant in South Korea met both primary and secondary efficacy endpoints of subjective total sleep time (sTST), subjective latency to sleep onset (sLSO) and subjective wake after sleep onset (sWASO)</li></ul> <p align="justify"><b>Tokyo, Japan and Cambridge, UK, 4 March 2026</b> – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that it has submitted a marketing authorisation application (MAA) to the http://www.streetinsider.com/Globe+Newswire/Nxera+Pharma+Submits+Marketing+Authorization+Application+for+Daridorexant+in+South+Korea/26106077.html Wed, 04 Mar 2026 03:54:00 +0000 4565 A.05768276 A.30594482 O.05105894 O.05733076 O.31501636 http://www.streetinsider.com/Globe+Newswire/Nxera+Pharma+Submits+Marketing+Authorization+Application+for+Daridorexant+in+South+Korea/26106077.html <ul type="disc"><li style="margin-top:22pt;">Daridorexant is a dual orexin receptor antagonist being developed in South Korea by Nxera for the treatment of adult patients with insomnia and is approved and marketed in Japan as QUVIVIQ®</li><li style="margin-top:22pt;">Phase 3 trial of daridorexant in South Korea met both primary and secondary efficacy endpoints of subjective total sleep time (sTST), subjective latency to sleep onset (sLSO) and subjective wake after sleep onset (sWASO)</li></ul> <p align="justify"><b>Tokyo, Japan and Cambridge, UK, 4 March 2026</b> – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that it has submitted a marketing authorisation application (MAA) to the http://www.streetinsider.com/Globe+Newswire/Nxera+Pharma+Submits+Marketing+Authorization+Application+for+Daridorexant+in+South+Korea/26106077.html Wed, 04 Mar 2026 03:54:00 +0000 4565 A.05768276 A.30594482 O.05105894 O.05733076 O.31501636 http://www.streetinsider.com/Board+Changes/Nxera+Pharma+nominates+Takeo+Morooka+as+external+director/25994584.html <p>Nxera Pharma Co., Ltd. (TSE: 4565) announced board changes including the nomination of Takeo Morooka as external director and the retirement of two current external directors, according to a company statement.</p> <p>The Tokyo-based biopharmaceutical company's board approved the nomination of Morooka, who currently serves on the company's Strategic Advisory Council. Miwa Seki and Noriaki Nagai will retire from their external director positions.</p> <p>The appointments require shareholder approval at the company's 36th Ordinary General Meeting scheduled for March 25, 2026.</p> <p>Morooka brings regulatory affairs and pharmaceutical policy experience from roles including medical officer at Japan's Ministry of Health and Welfare and the World Health http://www.streetinsider.com/Board+Changes/Nxera+Pharma+nominates+Takeo+Morooka+as+external+director/25994584.html Fri, 13 Feb 2026 05:34:45 +0000 4565 A.12755071 A.17568957 A.26835677 A.28234436 A.38112335 A.50203758 A.50205481 A.60012005 O.00005589 O.04889877 O.05105894 O.05324763 O.05371131 O.06037046 O.11480045 O.29426265 O.50923463 http://www.streetinsider.com/Board+Changes/Nxera+Pharma+nominates+Takeo+Morooka+as+external+director/25994584.html <p>Nxera Pharma Co., Ltd. (TSE: 4565) announced board changes including the nomination of Takeo Morooka as external director and the retirement of two current external directors, according to a company statement.</p> <p>The Tokyo-based biopharmaceutical company's board approved the nomination of Morooka, who currently serves on the company's Strategic Advisory Council. Miwa Seki and Noriaki Nagai will retire from their external director positions.</p> <p>The appointments require shareholder approval at the company's 36th Ordinary General Meeting scheduled for March 25, 2026.</p> <p>Morooka brings regulatory affairs and pharmaceutical policy experience from roles including medical officer at Japan's Ministry of Health and Welfare and the World Health http://www.streetinsider.com/Board+Changes/Nxera+Pharma+nominates+Takeo+Morooka+as+external+director/25994584.html Fri, 13 Feb 2026 05:34:45 +0000 4565 A.12755071 A.17568957 A.26835677 A.28234436 A.38112335 A.50203758 A.50205481 A.60012005 O.00005589 O.04889877 O.05105894 O.05324763 O.05371131 O.06037046 O.11480045 O.29426265 O.50923463 http://www.streetinsider.com/Board+Changes/Nxera+Pharma+nominates+Takeo+Morooka+as+external+director/25994584.html <p>Nxera Pharma Co., Ltd. (TSE: 4565) announced board changes including the nomination of Takeo Morooka as external director and the retirement of two current external directors, according to a company statement.</p> <p>The Tokyo-based biopharmaceutical company's board approved the nomination of Morooka, who currently serves on the company's Strategic Advisory Council. Miwa Seki and Noriaki Nagai will retire from their external director positions.</p> <p>The appointments require shareholder approval at the company's 36th Ordinary General Meeting scheduled for March 25, 2026.</p> <p>Morooka brings regulatory affairs and pharmaceutical policy experience from roles including medical officer at Japan's Ministry of Health and Welfare and the World Health http://www.streetinsider.com/Board+Changes/Nxera+Pharma+nominates+Takeo+Morooka+as+external+director/25994584.html Fri, 13 Feb 2026 05:34:45 +0000 4565 A.12755071 A.17568957 A.26835677 A.28234436 A.38112335 A.50203758 A.50205481 A.60012005 O.00005589 O.04889877 O.05105894 O.05324763 O.05371131 O.06037046 O.11480045 O.29426265 O.50923463 http://www.streetinsider.com/Board+Changes/Nxera+Pharma+nominates+Takeo+Morooka+as+external+director/25994584.html <p>Nxera Pharma Co., Ltd. (TSE: 4565) announced board changes including the nomination of Takeo Morooka as external director and the retirement of two current external directors, according to a company statement.</p> <p>The Tokyo-based biopharmaceutical company's board approved the nomination of Morooka, who currently serves on the company's Strategic Advisory Council. Miwa Seki and Noriaki Nagai will retire from their external director positions.</p> <p>The appointments require shareholder approval at the company's 36th Ordinary General Meeting scheduled for March 25, 2026.</p> <p>Morooka brings regulatory affairs and pharmaceutical policy experience from roles including medical officer at Japan's Ministry of Health and Welfare and the World Health http://www.streetinsider.com/Board+Changes/Nxera+Pharma+nominates+Takeo+Morooka+as+external+director/25994584.html Fri, 13 Feb 2026 05:34:45 +0000 4565 A.12755071 A.17568957 A.26835677 A.28234436 A.38112335 A.50203758 A.50205481 A.60012005 O.00005589 O.04889877 O.05105894 O.05324763 O.05371131 O.06037046 O.11480045 O.29426265 O.50923463 http://www.streetinsider.com/Board+Changes/Nxera+Pharma+nominates+Takeo+Morooka+as+external+director/25994584.html <p>Nxera Pharma Co., Ltd. (TSE: 4565) announced board changes including the nomination of Takeo Morooka as external director and the retirement of two current external directors, according to a company statement.</p> <p>The Tokyo-based biopharmaceutical company's board approved the nomination of Morooka, who currently serves on the company's Strategic Advisory Council. Miwa Seki and Noriaki Nagai will retire from their external director positions.</p> <p>The appointments require shareholder approval at the company's 36th Ordinary General Meeting scheduled for March 25, 2026.</p> <p>Morooka brings regulatory affairs and pharmaceutical policy experience from roles including medical officer at Japan's Ministry of Health and Welfare and the World Health http://www.streetinsider.com/Board+Changes/Nxera+Pharma+nominates+Takeo+Morooka+as+external+director/25994584.html Fri, 13 Feb 2026 05:34:45 +0000 4565 A.12755071 A.17568957 A.26835677 A.28234436 A.38112335 A.50203758 A.50205481 A.60012005 O.00005589 O.04889877 O.05105894 O.05324763 O.05371131 O.06037046 O.11480045 O.29426265 O.50923463